Plasma levels of tumor necrosis factor α and soluble tumor necrosis factor receptors in patients with narcolepsy

Archives of Internal Medicine

Volumn 166, Issue 16, 2006, Pages 1739-1743

  Himmerich, Hubertus ^a,e,f   Beitinger, Pierre A ^a   Fulda, Stephany ^a   Wehrle, Renate ^a   Linseisen, Jakob ^b,c   Wolfram, Günther ^b   Himmerich, Stephanie ^b   Gedrich, Kurt ^b   Wetter, Thomas C ^a   Pollmächer, Thomas ^a,d  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KLINIKUM INGOLSTADT   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NARCOLEPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; RECEPTORS, TUMOR NECROSIS FACTOR; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748791180     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.16.1739     Document Type: Article

References (40)

1. Choo KL, Guilleminault C. Narcolepsy and idiopathic hypersomnolence. Clin Chest Med. 1998;19:169-181.
2. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58:1826-1833.
3. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9:269-310.
4. Mignot E, Tafti M, Dement WC, Grumet FC. Narcolepsy and immunity. Adv Neuroimmunol. 1995;5:23-37.
5. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol. 2001;117:9-20.
6. Moller E, Bohme J, Valugerdi MA, Ridderstad A, Olerup O. Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of "autoreactive" T lymphocytes. Immunol Rev. 1990;118:5-19.
7. Dauvilliers Y. Neurodegenerative, autoimmune and genetic processes of human and animal narcolepsy. Rev Neurol (Paris). 2003;159(11)(suppl):6S83-6S87.
8. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-474.
9. Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D, Mullington J. Experimental immunomodulation, sleep, and sleepiness in humans. Ann N Y Acad Sci. 2000;917:488-499.
10. Deboer T, Fontana A, Tobler I. Tumor necrosis factor (TNF) ligand and TNF receptor deficiency affects sleep and the sleep EEG. J Neurophysiol. 2002;88:839-846.
11. Fang J, Wang Y, Krueger JM. Mice lacking the TNF 55 kDa receptor fail to sleep more after TNFalpha treatment. J Neurosci. 1997;17:5949-5955.
12. Takahashi S, Tooley DD, Kapas L, Fang J, Seyer JM, Krueger JM. Inhibition of tumor necrosis factor in the brain suppresses rabbit sleep. Pflugers Arch. 1995;431:155-160.
13. Takahashi S, Krueger JM. Inhibition of tumor necrosis factor prevents warming-induced sleep responses in rabbits. Am J Physiol. 1997;272:R1325-R1329.
14. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82:1313-1316.
15. Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol. 2001;107:165-170.
16. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord. 1998;12:215-227.
17. Puccioni-Sohler M, Rieckmann P, Kitze B, Lange P, Albrecht M, Felgenhauer K. A soluble form of tumour necrosis factor receptor in cerebrospinal fluid and serum of HTLV-I-associated myelopathy and other neurological diseases. J Neurol. 1995;242:239-242.
18. Okun ML, Giese S, Lin L, Einen M, Mignot E, Coussons-Read ME. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun. 2004;18:326-332.
19. Hinze-Selch D, Wetter TC, Zhang Y, et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology. 1998;50:1149-1152.
20. Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord. 1998;22:1239-1243.
21. Schuld A, Hebebrand J, Geller F, Pollmächer T. Increased body-mass index in patients with narcolepsy. Lancet. 2000;355:1274-1275.
22. Schuld A, Beitinger PA, Dalal M, et al. Increased body mass index (BMI) in male narcoleptic patients, but not in HLA-DR2-positive healthy male volunteers. Sleep Med. 2002;3:335-339.
23. Hohjoh H, Nakayama T, Ohashi J, et al. Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens. 1999;54:138-145.
24. Wieczorek S, Dahmen N, Jagiello P, Epplen JT, Gencik M. Polymorphisms of the tumor necrosis factor receptors: no association with narcolepsy in German patients. J Mol Med. 2003;81:87-90.
25. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs. 2000;9:497-514.
26. Peces R, Urra JM, de la Torre M. Influence of HLA-DR phenotype on tumor necrosis factor-alpha production in renal-transplant recipients. Nephron. 1995;71:180-183.
27. Schuld A, Blum WF, Uhr M, et al. Reduced leptin levels in human narcolepsy. Neuroendocrinology. 2000;72:195-198.
28. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962-971.
29. van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25:1759-1766.
30. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry. 2002;35:220-225.
31. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res. 2000;43:164-166.
32. Himmerich H, Koethe D, Schuld A, Yassouridis A, Pollmächer T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl). 2005;179:447-451.
33. Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol. 2002;146:325-331.
34. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000;24(suppl 4):S23-S27.
35. Beitinger PA, Dalal MA, Wehrle R, et al. Impaired glucose tolerance in patients with narcolepsy [abstract]. Pharmacopsychiatry. 2005;38:230.
36. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R1227-R1234.
37. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem. 2000;275:14608-14614.
38. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998;28:257-263.
39. Vandenabeele P, Declercq W, Vercammen D, et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992;176:1015-1024.
40. Grell M, Scheurich P, Meager A, Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res. 1993;12:143-148.